Featured Articles

81. Phase 1 Trials: Strategies For Site Selection And Dose-Escalation 11/18/2021

    This white paper explores key considerations for site selection and dose-escalation design strategies in early-phase oncology trials.

82. Streamlining Regulatory Submissions For A Novel Advanced Therapy Medicinal Product Trial 10/28/2021

    The European regulatory landscape for advanced therapy medicinal products (ATMPs) is complex, and the approval pathway depends on product classification. This case study describes how product classification may not always be clear-cut, given the proliferation of novel approaches to ATMP development.

83. A Primer On Cancer Immunotherapy Part 2: The Cancer Immune Response & Mechanisms Of Resistance 9/29/2021

    This article examines the rationale for combination therapies, mechanisms of resistance, and where to go from here.

84. Build A Better Oncology Patient Experience: Supporting Participants Throughout A Study 9/10/2021

    Patient recruitment gets all the attention at an oncology study’s inception, but enhancing patient engagement throughout the study bolsters retention, long-term follow-up participation, and the likelihood of patients volunteering in future trials.

85. A Primer On Cancer Immunotherapy Part 1: Goals And Major Approaches 8/27/2021

    This post provides an introduction to cancer immunotherapy, exploring its immunological basis and the fundamental principles guiding the development of new treatments.

86. Gene Therapy For Parkinson's Disease: Strategies And Operational Requirements 7/29/2021

    Gene therapy holds great promise as a potential treatment for Parkinson’s disease, a disorder for which currently available medications do not causally treat the underlying disease mechanisms. Download the available white paper to find out more.

87. Introduction To CAR T-Cell Therapy Part 2: Additional Considerations & Future Opportunities 7/15/2021

    Beginning in 2017 with the approvals of tisagenlecleucel (Kymriah™) and axicabtagene ciloleucel (Yescarta™), read how chimeric antigen receptor (CAR) T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies.

88. Introduction To CAR T-Cell Therapy Part 1: Background & Current Development Landscape 7/13/2021

    With the approvals of tisagenlecleucel (KYMRIAH) and axicabtagene ciloleucel (YESCARTA) last year, chimeric antigen receptor (CAR) T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies. Learn about the development of CAR T-cell therapy as well as its advantages and challenges.

89. Can Technology Replace Medical Coders? 6/29/2021

    All data generated in a clinical trial must be uniformly interpreted to ensure accurate results. Correct medical coding plays a critical role — and how that coding happens may be shifting. How is technology affecting the process of medical coding in clinical trials? Watch our webinar to find out.

90. Dermatology: The Changing Landscape Of Psoriasis Treatment 6/29/2021

    Over the past two decades, biologic therapies have revolutionized the treatment of psoriasis, with more than half of treated patients now able to achieve essentially complete clearing of their disease. Learn more about these therapies as well as new topical and oral therapies that are emerging.